On March 29, 2023, Hybribio and MGI Tech signed an agreement to reach strategic cooperation in the direction of high-throughput sequencing platform to expand international market. MGI Tech will provide DNBSEQ sequencing platform to help Hybribio carry out the application development and clinical translation of precision medicine. The two parties will also make use of their respective advantages to expand the international market and contribute to the universal access to genetic testing technology.

At the signing ceremony, Mr. Guan Chisheng, Director and Executive Vice President of Hybribio, and Ms. Jiang Hui, Chief Operating Officer of MGI Tech, signed the agreement on behalf of both parties respectively.

Mr. Guan Chisheng of Hybribio said, "Hybribio has been deeply engaged in the molecular testing field for more than 20 years, always paying attention to the development and needs of the medical industry, and constantly introducing efficient and intelligent innovative solutions to make precision medical services come into practice. Both Hybribio and MGI Tech are independent R&D-driven enterprises, and their renewed cooperation is a strong combination of national biotechnology enterprises and a highly integrated advantage of their respective fields."

Ms. Jiang Hui of MGI Tech said, "Based on DNBSEQ's independent core technology, MGI Tech has built a full-coverage sequencer matrix of 'low-throughput-middle-throughput-high-throughput-ultra-high-throughput', providing global users with one more choice. We look forward to complementary advantages and win-win synergy with Hybribio and join hands to bring more in-depth and comprehensive breakthroughs in clinical applications of high-throughput sequencing in precision medicine, to step out of globalization and high quality, and to accelerate the process of genetic technology for everyone."

About Hybribio

Hybribio is the leading supplier of nucleic acid molecular diagnostic products in China, with a complete operation chain, from research and development, production, to sales. In 2017, Hybribio was listed in GEM of Shenzhen Stock Exchange.

Hybribio developed the IVD platform based on patented technology - “Flow-through Hybridization”, which has been licensed by The University of Hong Kong, and established two major R&D lines - infectious pathogen detection and genetic disease detection. Hybribio's products, which have been approved by CFDA and have obtained CE-IVD licenses, have been extensively used in medical and research laboratories in European and Asian countries. Working with partners from different countries, Hybribio's sales and marketing teams aim for providing an effective strategic marketing plan catered for different markets. More than 25 countries in Asia Pacific, South East Asia, Middle East, Europe, Africa, and South America use our IVD products for national screening, clinical and research purposes. So far, Hybribio’s diagnostic reagents have been exported to nearly 30 countries.

About MGI Tech

MGI Tech Co., Ltd. (referred to as MGI)  is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

As of December 31, 2021, MGI has 2,050 employees, and 35% of whom are R&D personnel. Founded in 2016, MGI operates in more than 80 countries and regions, serving more than 1,300 customers. It has established scientific research and production bases, global training and service network in many countries and regions around the world. MGI is one of the few companies in the world that can independently develop and mass-produce clinical high-throughput gene sequencers. Providing real-time, comprehensive, life-long solutions, its vision is to lead life science innovation.